anticoagulant for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. adjuvant therapies
vs. anticoagulant
vs. anticoagulant, curative dose
vs. anticoagulant, prophylactic dose
vs. control
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 NCT02735707

anticoagulant, curative dose vs. anticoagulant, prophylactic dose

COVID-19 severe or critically

COVID-PACT, 2022

anticoagulant, curative dose vs. anticoagulant, prophylactic dose

COVID-19 severe or critically

Tang, 2020

anticoagulant, prophylactic dose vs. control

COVID-19 severe or critically

INSPIRATION, 2021 NCT04486508

anticoagulation, intermediate prophylactic dose vs. anticoagulant, prophylactic dose

COVID-19 severe or critically

NCT04445935, 0 NCT04445935

Bivalirudin vs. standard of care

COVID-19 severe or critically

ATTACC (Houston), 0 NCT04372589

heparin at therapeutic dose vs. control

COVID-19 severe or critically

ACTIV-4a (heparin), 0 NCT04505774

heparin at therapeutic dose vs. control

COVID-19 severe or critically

REMAP-CAP Anticoagulation, 0 NCT02735707

heparin at therapeutic dose vs. control

COVID-19 severe or critically

NCT04445623, 0 NCT04445623

P2Y12 inhibitors vs. placebo

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open